fmi stock quote  foundation medicine inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  fmi foundation medicine inc common stock quote  summary data       get fmi alerts delayed  data as of jul      find a broker to begin trading fmi now exchangenasdaq industry health care community rating view    fmi after hours fmi     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock       year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple ne forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec we are a molecular information company focused on fundamentally changing the way in which patients with cancer are evaluated and treated we believe an informationbased approach to making clinical treatment decisions based on comprehensive genomic profiling or cgp will become standard of care for patients with cancer we derive revenue from selling products that are enabled by our molecular information platform to physicians and biopharmaceutical companies our platform includes proprietary methods and algorithms for analyzing specimens across all types of cancer and for incorporating that information into clinical care in a concise and userfriendly fashion our products provide genomic information about each patients individual cancer obtained from that analysis enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies more effectively   more    risk grade where does fmi fit in the risk graph news for fmi biotech bonanza the next leg up   pm  seeking alpha tuesdays etf with unusual volume pth   pm  bnk invest will the federal reserve avoid a slowdown   am  seeking alpha etf winner of h and its top  stocks   am  zackscom biotechs best chance has gotten even better   pm  seeking alpha  subscribe more fmi news  commentary read fmi press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex foundation medicine  wikipedia foundation medicine from wikipedia the free encyclopedia jump to navigation search foundation medicine inc traded as nasdaq fmi headquarters cambridge massachusetts united states key people troy cox ceo steve kafka coo david daly cco products foundationone foundationone heme foundationact foundationfocus cdxbrca owners hoffmannla roche   number of employees  march  website official website foundation medicine inc is a public american company based in cambridge massachusetts which develops manufactures and sells genomic analysis diagnostics for solid and circulating cancers the companys tests are based on nextgeneration sequencing technology foundation medicine went public in august  its stock is traded on the new york stock exchange under the symbol fmi in  revenue reached  million as of march update the company had  employees the companys flagship product was foundationone followed by the foundationone heme diagnostic test being for blood cancers in november and december  the company established agreements with cota cancer outcomes tracking and analysis and flatiron health respectively aimed at increasing the volume of genomic and clinical patient data available to it in  roche announced a plan to purchase a  stake in the company through a us purchase of newly issued shares roche also announced an intention to invest us toward foundation medicines operations development and rd activities foundation medicine also has business agreements with johnson  johnson and novartis the companys chief executive officer ceo is troy cox the companys chief operating officer coo is steve kafka the companys chief commercial officer cco is david daly see alsoedit drug discovery personalized medicine referencesedit  staff  january  cambridge startup soars on roche stake business the boston globe   staff  january  foundation medicine on the added value of ngs cancer tests clinical informatics news needham massachusetts united states cambridge healthtech institute   a b c d seiffert don  december  foundation medicine still growing a year after launching bloodcancer test boston business journal   a b byerly max  january  foundation medicine receives  consensus pt from analysts nysefmi ticker report sandyville west virginia united states   the  fastestgrowing biotech firms in the bay state boston business journal march     a b seiffert don  november  foundation medicines shares gain on flurry of good news ahead of earnings call boston business journal   a b c zacks equity research  january  roche to acquire up to  interest in foundation medicine analyst blog zacks investment research  this article related to a manufacturing company is a stub you can help wikipedia by expanding it v t e this article about a medical pharmaceutical or biotechnological corporation or company is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitlefoundationmedicineoldid categories biotechnology companies of the united statescompanies based in cambridge massachusettscompanies listed on nasdaqgenomics companiesmanufacturing company stubsmedical company stubshidden categories official website not in wikidataarticles containing potentially dated statements from march all articles containing potentially dated statementsall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages עברית edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view   foundation medicine skip to contentfoundation medicinelog inmenuthe relentless pursuit of betterwe never give up we strive to do more for cancer patients  through richer science deeper insights and stronger partnerships  providing better cancer care today and fueling better cancer care tomorrow foundation medicine is a worldleading molecular insights company connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands better care todaygenomic testingcomprehensive genomic profilingour portfolio of genomic tests is the leading platform for comprehensive genomic profiling we interrogate more than  genes across all four classes of genomic alterations to help understand the genomic makeup of a patients tumor molecular insightsvaluable insights actionable optionswe match each patient’s unique profile to known targeted therapies immunotherapies and clinical trials and offer decision support tools financial assistance and technology solutions to help streamline patient care patient storydealing with cancer is not just dealing with the cancer it’s treating the whole personchristine bray ovarian cancer survivor shares her journey to remission after obtaining foundationone® a comprehensive genomic profiling test playbetter care tomorrowmore than numbersinsights not just information our unique knowledgebase foundationcore™ is one of the worlds largest cancer genomic databases with more than  anonymized patient records designed to help researchers and biopharma companies advance precision medicine develop new therapies and design better trials supporting drug developmentthe preferred partner to biopharmawe partner with drug developers throughout every stage of drug research and development from target discovery to commercial launch today we are working with more than  biopharma partners to accelerate new biomarkerdriven treatments advancing cancer careeach patient’s cancer informs all those cases that will come in the futurelearn more about how we are advancing the field with our foundationcorepowered data analytics platform and our groundbreaking  patient realworld research dataset gaurav singal md vp data products  strategy better care togethercollective advancesthe power of collaborationby sharing our genomic data we empower researchers on the front lines to generate new connections and insights today we proudly participate in a number of sharing initiatives to accelerate research efforts transforming cancer carecultivating an ecosystem of partnersevery insight we gain towards better cancer care is multiplied by a hyperconnected network of physicians biopharma researchers patient advocacy organizations and worldleading medical centers together we are transforming cancer care from the blogdiving deeper into cancer immunotherapy biomarkersphil stephens phdchief scientific officercancer immunotherapy is transforming the treatment landscape for many types of cancer but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field personalized targeted therapies have traditionally been prescribed based on the presence of single mutations – but immunotherapy isn’t so simple today one of the most common biomarkers for immunotherapy is a protein called pdl unfortunately while patients with high pdl are more likely to respond to immunotherapy many with high pdl don’t respond and many with low pdl do read the articlejoin us in the pursuit of betterfind out more about genomic testing learn more about us or read the latest updates from our blog foundation medicine skip to contentfoundation medicinelog inmenuthe relentless pursuit of betterwe never give up we strive to do more for cancer patients  through richer science deeper insights and stronger partnerships  providing better cancer care today and fueling better cancer care tomorrow foundation medicine is a worldleading molecular insights company connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands better care todaygenomic testingcomprehensive genomic profilingour portfolio of genomic tests is the leading platform for comprehensive genomic profiling we interrogate more than  genes across all four classes of genomic alterations to help understand the genomic makeup of a patients tumor molecular insightsvaluable insights actionable optionswe match each patient’s unique profile to known targeted therapies immunotherapies and clinical trials and offer decision support tools financial assistance and technology solutions to help streamline patient care patient storydealing with cancer is not just dealing with the cancer it’s treating the whole personchristine bray ovarian cancer survivor shares her journey to remission after obtaining foundationone® a comprehensive genomic profiling test playbetter care tomorrowmore than numbersinsights not just information our unique knowledgebase foundationcore™ is one of the worlds largest cancer genomic databases with more than  anonymized patient records designed to help researchers and biopharma companies advance precision medicine develop new therapies and design better trials supporting drug developmentthe preferred partner to biopharmawe partner with drug developers throughout every stage of drug research and development from target discovery to commercial launch today we are working with more than  biopharma partners to accelerate new biomarkerdriven treatments advancing cancer careeach patient’s cancer informs all those cases that will come in the futurelearn more about how we are advancing the field with our foundationcorepowered data analytics platform and our groundbreaking  patient realworld research dataset gaurav singal md vp data products  strategy better care togethercollective advancesthe power of collaborationby sharing our genomic data we empower researchers on the front lines to generate new connections and insights today we proudly participate in a number of sharing initiatives to accelerate research efforts transforming cancer carecultivating an ecosystem of partnersevery insight we gain towards better cancer care is multiplied by a hyperconnected network of physicians biopharma researchers patient advocacy organizations and worldleading medical centers together we are transforming cancer care from the blogdiving deeper into cancer immunotherapy biomarkersphil stephens phdchief scientific officercancer immunotherapy is transforming the treatment landscape for many types of cancer but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field personalized targeted therapies have traditionally been prescribed based on the presence of single mutations – but immunotherapy isn’t so simple today one of the most common biomarkers for immunotherapy is a protein called pdl unfortunately while patients with high pdl are more likely to respond to immunotherapy many with high pdl don’t respond and many with low pdl do read the articlejoin us in the pursuit of betterfind out more about genomic testing learn more about us or read the latest updates from our blog foundation medicine skip to contentfoundation medicinelog inmenuthe relentless pursuit of betterwe never give up we strive to do more for cancer patients  through richer science deeper insights and stronger partnerships  providing better cancer care today and fueling better cancer care tomorrow foundation medicine is a worldleading molecular insights company connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands better care todaygenomic testingcomprehensive genomic profilingour portfolio of genomic tests is the leading platform for comprehensive genomic profiling we interrogate more than  genes across all four classes of genomic alterations to help understand the genomic makeup of a patients tumor molecular insightsvaluable insights actionable optionswe match each patient’s unique profile to known targeted therapies immunotherapies and clinical trials and offer decision support tools financial assistance and technology solutions to help streamline patient care patient storydealing with cancer is not just dealing with the cancer it’s treating the whole personchristine bray ovarian cancer survivor shares her journey to remission after obtaining foundationone® a comprehensive genomic profiling test playbetter care tomorrowmore than numbersinsights not just information our unique knowledgebase foundationcore™ is one of the worlds largest cancer genomic databases with more than  anonymized patient records designed to help researchers and biopharma companies advance precision medicine develop new therapies and design better trials supporting drug developmentthe preferred partner to biopharmawe partner with drug developers throughout every stage of drug research and development from target discovery to commercial launch today we are working with more than  biopharma partners to accelerate new biomarkerdriven treatments advancing cancer careeach patient’s cancer informs all those cases that will come in the futurelearn more about how we are advancing the field with our foundationcorepowered data analytics platform and our groundbreaking  patient realworld research dataset gaurav singal md vp data products  strategy better care togethercollective advancesthe power of collaborationby sharing our genomic data we empower researchers on the front lines to generate new connections and insights today we proudly participate in a number of sharing initiatives to accelerate research efforts transforming cancer carecultivating an ecosystem of partnersevery insight we gain towards better cancer care is multiplied by a hyperconnected network of physicians biopharma researchers patient advocacy organizations and worldleading medical centers together we are transforming cancer care from the blogdiving deeper into cancer immunotherapy biomarkersphil stephens phdchief scientific officercancer immunotherapy is transforming the treatment landscape for many types of cancer but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field personalized targeted therapies have traditionally been prescribed based on the presence of single mutations – but immunotherapy isn’t so simple today one of the most common biomarkers for immunotherapy is a protein called pdl unfortunately while patients with high pdl are more likely to respond to immunotherapy many with high pdl don’t respond and many with low pdl do read the articlejoin us in the pursuit of betterfind out more about genomic testing learn more about us or read the latest updates from our blog foundation medicine  wikipedia foundation medicine from wikipedia the free encyclopedia jump to navigation search foundation medicine inc traded as nasdaq fmi headquarters cambridge massachusetts united states key people troy cox ceo steve kafka coo david daly cco products foundationone foundationone heme foundationact foundationfocus cdxbrca owners hoffmannla roche   number of employees  march  website official website foundation medicine inc is a public american company based in cambridge massachusetts which develops manufactures and sells genomic analysis diagnostics for solid and circulating cancers the companys tests are based on nextgeneration sequencing technology foundation medicine went public in august  its stock is traded on the new york stock exchange under the symbol fmi in  revenue reached  million as of march update the company had  employees the companys flagship product was foundationone followed by the foundationone heme diagnostic test being for blood cancers in november and december  the company established agreements with cota cancer outcomes tracking and analysis and flatiron health respectively aimed at increasing the volume of genomic and clinical patient data available to it in  roche announced a plan to purchase a  stake in the company through a us purchase of newly issued shares roche also announced an intention to invest us toward foundation medicines operations development and rd activities foundation medicine also has business agreements with johnson  johnson and novartis the companys chief executive officer ceo is troy cox the companys chief operating officer coo is steve kafka the companys chief commercial officer cco is david daly see alsoedit drug discovery personalized medicine referencesedit  staff  january  cambridge startup soars on roche stake business the boston globe   staff  january  foundation medicine on the added value of ngs cancer tests clinical informatics news needham massachusetts united states cambridge healthtech institute   a b c d seiffert don  december  foundation medicine still growing a year after launching bloodcancer test boston business journal   a b byerly max  january  foundation medicine receives  consensus pt from analysts nysefmi ticker report sandyville west virginia united states   the  fastestgrowing biotech firms in the bay state boston business journal march     a b seiffert don  november  foundation medicines shares gain on flurry of good news ahead of earnings call boston business journal   a b c zacks equity research  january  roche to acquire up to  interest in foundation medicine analyst blog zacks investment research  this article related to a manufacturing company is a stub you can help wikipedia by expanding it v t e this article about a medical pharmaceutical or biotechnological corporation or company is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitlefoundationmedicineoldid categories biotechnology companies of the united statescompanies based in cambridge massachusettscompanies listed on nasdaqgenomics companiesmanufacturing company stubsmedical company stubshidden categories official website not in wikidataarticles containing potentially dated statements from march all articles containing potentially dated statementsall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages עברית edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view events  presentations  foundation medicine skip to content foundation medicine log in menu investors  press events  presentations jump to a page investor relations corporate governance sec filings events  presentations investor faqs stock information analyst coverage press releases quarterly results email alerts executive team filter events calander select all events scientific meetings upcoming events date event details remind me august    pm et foundation medicine second quarter  financial results conference call listen to webcast sign up for email alerts foundation medicine second quarter  financial results conference call remind me please sign up for email alerts close outlook google sep   esmo  conference location madrid spain sign up for email alerts esmo  conference remind me please sign up for email alerts close outlook google oct   cap  college of american pathologists location washington dc sign up for email alerts cap  college of american pathologists remind me please sign up for email alerts close outlook google dec   wclc world conference on lung cancer location vienna austria sign up for email alerts wclc world conference on lung cancer remind me please sign up for email alerts close outlook google dec   san antonio breast cancer symposium location san antonio tx sign up for email alerts san antonio breast cancer symposium remind me please sign up for email alerts close outlook google dec   ash  american society of hematology annual meeting location atlanta ga sign up for email alerts ash  american society of hematology annual meeting remind me please sign up for email alerts close outlook google past events date event details location jun   the liquid biopsy summit location san francisco ca san francisco ca june    am ct william blair growth stock conference location chicago listen to webcast chicago june    am pt goldman sachs annual healthcare conference location rancho palos verdes ca listen to webcast rancho palos verdes ca jun   asco  american society of clinical oncology annual meeting location chicago illinois chicago illinois shareholder tools email alerts snapshot rss print email share facebook google linkedin twitter email rss close dialogwelcome backsign into your accountemail addresspasswordforgot passwordlog indonâ€™t have an accountyou can sign up onlinesign up foundation medicine skip to contentfoundation medicinelog inmenuthe relentless pursuit of betterwe never give up we strive to do more for cancer patients  through richer science deeper insights and stronger partnerships  providing better cancer care today and fueling better cancer care tomorrow foundation medicine is a worldleading molecular insights company connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands better care todaygenomic testingcomprehensive genomic profilingour portfolio of genomic tests is the leading platform for comprehensive genomic profiling we interrogate more than  genes across all four classes of genomic alterations to help understand the genomic makeup of a patients tumor molecular insightsvaluable insights actionable optionswe match each patient’s unique profile to known targeted therapies immunotherapies and clinical trials and offer decision support tools financial assistance and technology solutions to help streamline patient care patient storydealing with cancer is not just dealing with the cancer it’s treating the whole personchristine bray ovarian cancer survivor shares her journey to remission after obtaining foundationone® a comprehensive genomic profiling test playbetter care tomorrowmore than numbersinsights not just information our unique knowledgebase foundationcore™ is one of the worlds largest cancer genomic databases with more than  anonymized patient records designed to help researchers and biopharma companies advance precision medicine develop new therapies and design better trials supporting drug developmentthe preferred partner to biopharmawe partner with drug developers throughout every stage of drug research and development from target discovery to commercial launch today we are working with more than  biopharma partners to accelerate new biomarkerdriven treatments advancing cancer careeach patient’s cancer informs all those cases that will come in the futurelearn more about how we are advancing the field with our foundationcorepowered data analytics platform and our groundbreaking  patient realworld research dataset gaurav singal md vp data products  strategy better care togethercollective advancesthe power of collaborationby sharing our genomic data we empower researchers on the front lines to generate new connections and insights today we proudly participate in a number of sharing initiatives to accelerate research efforts transforming cancer carecultivating an ecosystem of partnersevery insight we gain towards better cancer care is multiplied by a hyperconnected network of physicians biopharma researchers patient advocacy organizations and worldleading medical centers together we are transforming cancer care from the blogdiving deeper into cancer immunotherapy biomarkersphil stephens phdchief scientific officercancer immunotherapy is transforming the treatment landscape for many types of cancer but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field personalized targeted therapies have traditionally been prescribed based on the presence of single mutations – but immunotherapy isn’t so simple today one of the most common biomarkers for immunotherapy is a protein called pdl unfortunately while patients with high pdl are more likely to respond to immunotherapy many with high pdl don’t respond and many with low pdl do read the articlejoin us in the pursuit of betterfind out more about genomic testing learn more about us or read the latest updates from our blog foundation medicine skip to contentfoundation medicinelog inmenuthe relentless pursuit of betterwe never give up we strive to do more for cancer patients  through richer science deeper insights and stronger partnerships  providing better cancer care today and fueling better cancer care tomorrow foundation medicine is a worldleading molecular insights company connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands better care todaygenomic testingcomprehensive genomic profilingour portfolio of genomic tests is the leading platform for comprehensive genomic profiling we interrogate more than  genes across all four classes of genomic alterations to help understand the genomic makeup of a patients tumor molecular insightsvaluable insights actionable optionswe match each patient’s unique profile to known targeted therapies immunotherapies and clinical trials and offer decision support tools financial assistance and technology solutions to help streamline patient care patient storydealing with cancer is not just dealing with the cancer it’s treating the whole personchristine bray ovarian cancer survivor shares her journey to remission after obtaining foundationone® a comprehensive genomic profiling test playbetter care tomorrowmore than numbersinsights not just information our unique knowledgebase foundationcore™ is one of the worlds largest cancer genomic databases with more than  anonymized patient records designed to help researchers and biopharma companies advance precision medicine develop new therapies and design better trials supporting drug developmentthe preferred partner to biopharmawe partner with drug developers throughout every stage of drug research and development from target discovery to commercial launch today we are working with more than  biopharma partners to accelerate new biomarkerdriven treatments advancing cancer careeach patient’s cancer informs all those cases that will come in the futurelearn more about how we are advancing the field with our foundationcorepowered data analytics platform and our groundbreaking  patient realworld research dataset gaurav singal md vp data products  strategy better care togethercollective advancesthe power of collaborationby sharing our genomic data we empower researchers on the front lines to generate new connections and insights today we proudly participate in a number of sharing initiatives to accelerate research efforts transforming cancer carecultivating an ecosystem of partnersevery insight we gain towards better cancer care is multiplied by a hyperconnected network of physicians biopharma researchers patient advocacy organizations and worldleading medical centers together we are transforming cancer care from the blogdiving deeper into cancer immunotherapy biomarkersphil stephens phdchief scientific officercancer immunotherapy is transforming the treatment landscape for many types of cancer but identifying those people most likely to benefit from these new treatments is one of the biggest hurdles facing the field personalized targeted therapies have traditionally been prescribed based on the presence of single mutations – but immunotherapy isn’t so simple today one of the most common biomarkers for immunotherapy is a protein called pdl unfortunately while patients with high pdl are more likely to respond to immunotherapy many with high pdl don’t respond and many with low pdl do read the articlejoin us in the pursuit of betterfind out more about genomic testing learn more about us or read the latest updates from our blog foundation medicine  wikipedia foundation medicine from wikipedia the free encyclopedia jump to navigation search foundation medicine inc traded as nasdaq fmi headquarters cambridge massachusetts united states key people troy cox ceo steve kafka coo david daly cco products foundationone foundationone heme foundationact foundationfocus cdxbrca owners hoffmannla roche   number of employees  march  website official website foundation medicine inc is a public american company based in cambridge massachusetts which develops manufactures and sells genomic analysis diagnostics for solid and circulating cancers the companys tests are based on nextgeneration sequencing technology foundation medicine went public in august  its stock is traded on the new york stock exchange under the symbol fmi in  revenue reached  million as of march update the company had  employees the companys flagship product was foundationone followed by the foundationone heme diagnostic test being for blood cancers in november and december  the company established agreements with cota cancer outcomes tracking and analysis and flatiron health respectively aimed at increasing the volume of genomic and clinical patient data available to it in  roche announced a plan to purchase a  stake in the company through a us purchase of newly issued shares roche also announced an intention to invest us toward foundation medicines operations development and rd activities foundation medicine also has business agreements with johnson  johnson and novartis the companys chief executive officer ceo is troy cox the companys chief operating officer coo is steve kafka the companys chief commercial officer cco is david daly see alsoedit drug discovery personalized medicine referencesedit  staff  january  cambridge startup soars on roche stake business the boston globe   staff  january  foundation medicine on the added value of ngs cancer tests clinical informatics news needham massachusetts united states cambridge healthtech institute   a b c d seiffert don  december  foundation medicine still growing a year after launching bloodcancer test boston business journal   a b byerly max  january  foundation medicine receives  consensus pt from analysts nysefmi ticker report sandyville west virginia united states   the  fastestgrowing biotech firms in the bay state boston business journal march     a b seiffert don  november  foundation medicines shares gain on flurry of good news ahead of earnings call boston business journal   a b c zacks equity research  january  roche to acquire up to  interest in foundation medicine analyst blog zacks investment research  this article related to a manufacturing company is a stub you can help wikipedia by expanding it v t e this article about a medical pharmaceutical or biotechnological corporation or company is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitlefoundationmedicineoldid categories biotechnology companies of the united statescompanies based in cambridge massachusettscompanies listed on nasdaqgenomics companiesmanufacturing company stubsmedical company stubshidden categories official website not in wikidataarticles containing potentially dated statements from march all articles containing potentially dated statementsall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages עברית edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view foundation medicine  wikipedia foundation medicine from wikipedia the free encyclopedia jump to navigation search foundation medicine inc traded as nasdaq fmi headquarters cambridge massachusetts united states key people troy cox ceo steve kafka coo david daly cco products foundationone foundationone heme foundationact foundationfocus cdxbrca owners hoffmannla roche   number of employees  march  website official website foundation medicine inc is a public american company based in cambridge massachusetts which develops manufactures and sells genomic analysis diagnostics for solid and circulating cancers the companys tests are based on nextgeneration sequencing technology foundation medicine went public in august  its stock is traded on the new york stock exchange under the symbol fmi in  revenue reached  million as of march update the company had  employees the companys flagship product was foundationone followed by the foundationone heme diagnostic test being for blood cancers in november and december  the company established agreements with cota cancer outcomes tracking and analysis and flatiron health respectively aimed at increasing the volume of genomic and clinical patient data available to it in  roche announced a plan to purchase a  stake in the company through a us purchase of newly issued shares roche also announced an intention to invest us toward foundation medicines operations development and rd activities foundation medicine also has business agreements with johnson  johnson and novartis the companys chief executive officer ceo is troy cox the companys chief operating officer coo is steve kafka the companys chief commercial officer cco is david daly see alsoedit drug discovery personalized medicine referencesedit  staff  january  cambridge startup soars on roche stake business the boston globe   staff  january  foundation medicine on the added value of ngs cancer tests clinical informatics news needham massachusetts united states cambridge healthtech institute   a b c d seiffert don  december  foundation medicine still growing a year after launching bloodcancer test boston business journal   a b byerly max  january  foundation medicine receives  consensus pt from analysts nysefmi ticker report sandyville west virginia united states   the  fastestgrowing biotech firms in the bay state boston business journal march     a b seiffert don  november  foundation medicines shares gain on flurry of good news ahead of earnings call boston business journal   a b c zacks equity research  january  roche to acquire up to  interest in foundation medicine analyst blog zacks investment research  this article related to a manufacturing company is a stub you can help wikipedia by expanding it v t e this article about a medical pharmaceutical or biotechnological corporation or company is a stub you can help wikipedia by expanding it v t e retrieved from httpsenwikipediaorgwindexphptitlefoundationmedicineoldid categories biotechnology companies of the united statescompanies based in cambridge massachusettscompanies listed on nasdaqgenomics companiesmanufacturing company stubsmedical company stubshidden categories official website not in wikidataarticles containing potentially dated statements from march all articles containing potentially dated statementsall stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages עברית edit links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view stock information  foundation medicine skip to content foundation medicine log in menu investors  press stock information jump to a page investor relations corporate governance sec filings events  presentations investor faqs stock information analyst coverage press releases quarterly results email alerts executive team price  open  previous close  day high  day low  change    change  volume  week high  week low  stock chart benchmark benchmark nasdaq nyse sp  amex compare area graph ohlc line graph candlestick time intraday  day  month  month  months  year  years  years  years range update from to the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by edgar online both third party services and foundation medicine inc does not maintain or provide information directly to this service stock information is delayed approximately  minutes the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by nasdaq omx both third party services and foundation medicine inc does not maintain or provide information directly to this service stock information is delayed approximately  minutes sign up for email alerts foundation medicine inc is covered by several analysts learn more about email alerts shareholder tools email alerts snapshot rss print email share facebook google linkedin twitter email rss close dialogwelcome backsign into your accountemail addresspasswordforgot passwordlog indonâ€™t have an accountyou can sign up onlinesign up foundation medicine inc private company information  bloomberg july    pm et biotechnology company overview of foundation medicine inc snapshot people company overview foundation medicine inc provides various molecular information products in the united states the company’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer as well as for incorporating that information into clinical care and offers genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies it provides clinical products such as foundationone for solid tumors foundationone heme for bloodbased cancers or hematologic malignancies including leukemia lymphoma and myeloma as foundation medicine inc provides various molecular information products in the united states the company’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer as well as for incorporating that information into clinical care and offers genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies it provides clinical products such as foundationone for solid tumors foundationone heme for bloodbased cancers or hematologic malignancies including leukemia lymphoma and myeloma as well as sarcomas and pediatric cancers foundation assay for circulating tumor foundationfocus cdxbrca a diagnostic assay to aid in identifying women with ovarian cancer the company also offers foundationcore a knowledgebase to publish scientific and medical advances and foster relationships throughout the oncology community in addition it has strategic collaboration agreements with wuxi pharmatech inc f hoffmannla roche ltd and genentech inc the company was founded in  and is headquartered in cambridge massachusetts foundation medicine inc is a subsidiary of roche holdings inc detailed description  second streetcambridge ma united statesfounded in  employees phone  fax  wwwfoundationmedicinecom key executives for foundation medicine inc dr steven kafka phd president  coo age  total annual compensation k mr david j daly chief commercial officer  gm of clinical oncology solutions age  total annual compensation k compensation as of fiscal year  foundation medicine inc key developments kura oncology establishes collaboration with foundation medicine to support tipifarnib development in hras mutant head and neck cancer jul   kura oncology inc announced it has entered into a collaboration agreement with foundation medicine inc to support patient enrollment for kura’s clinical program for tipifarnib in patients with relapsed andor refractory hras mutant squamous cell carcinoma of the head and neck scchn through this collaboration foundation medicine’s smarttrials precision enrollment program will contact physicians treating individuals across the us diagnosed with scchn whose tumors harbor hras mutations as detected in the course of routine clinical care the treating physicians will be contacted and informed of kura’s ongoing phase  study of tipifarnib including relevant details about the trial including trial patient characteristics and investigational centers to assist the physician in evaluating tipifarnib as a potential treatment option guardant health files lanham act lawsuit against foundation medicine inc alleging false advertising jun   guardant health filed a lawsuit against foundation medicine inc fmi for false advertising and unfair competition guardant health initiated the litigation on june   under the lanham act and related california statutes in the us district court for the northern district of california the complaint alleges that fmis advertising harms guardant health and patients by misleading oncologists about the accuracy and sensitivity of the guardant® assay guardant healths comprehensive liquid biopsy as well as fmis own assays the complaint contends that although fmi routinely promotes its own liquid biopsy as the best in class with unparalleled sensitivity multiple studies including some presented by fmi at a recent scientific conference contradict these claims guardant health has asked the court to enjoin fmi from continuing to make or disseminate false or misleading statements about the performance of its own assays as well as guardant and to require fmi to retract remove and correct these false and misleading advertising claims foundation medicine inc announces resignation of david j daly as chief commercial officer and general manager clinical oncology solutions effective august   jun   on june   the board of directors of foundation medicine inc received notice that david j daly intends to resign as chief commercial officer and general manager clinical oncology solutions of the company due to personal reasons the resignation will be effective as of august   similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact foundation medicine inc please visit wwwfoundationmedicinecom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising fminasdaq gs stock quote  foundation medicine inc  bloomberg markets error could not add to watchlist x  watchlist foundation medicine inc fmius nasdaq gs usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  kura oncology establishes collaboration with foundation medicine to support tipifarnib development in hras mutant head and neck  foundation medicine announces timing for second quarter  financial results and conference call  asco and foundation medicine announce collaboration to help research sites identify potential participants for the targeted  foundation medicine to identify patients eligible for national cancer institute’s ncimatch molecular analysis for therapy  foundation medicine to present at upcoming investor conferences  clovis oncology announces presentations at  asco annual meeting  flatiron health announces collaborative research to be presented at asco’s  annual meeting  foundation medicine and its collaborators to present new data at asco  supporting the integration of comprehensive genomic  foundation medicine announces  first quarter results and recent highlights  h biomedicine extends collaboration with foundation medicine to develop precision therapies for cancer there are currently no press releases for this ticker please check back later profile foundation medicine inc develops cancer diagnostic technology the company offers cancer genomics laboratory tests enabling the personalization of cancer treatments foundation medicine serves the biomedical sector in the united states address  second streetcambridge ma united states phone  website wwwfoundationmedicinecom executives board members troy cox chief executive officer steven j kafka steve presidentcoo jason ryan cfotreasurer david j daly dave chief commercial ofcrgen mgrclinical vincent a miller chief medical officer show more flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     foundation medicine foundationatcg  twitter skip to content home home home current page moments moments moments current page search query search twitter saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  language english bahasa indonesia bahasa melayu català čeština dansk deutsch english uk español filipino français hrvatski italiano magyar nederlands norsk polski português română slovenčina suomi svenska tiếng việt türkçe ελληνικά български език русский српски українська мова עִבְרִית العربية فارسی मराठी हिन्दी বাংলা ગુજરાતી தமிழ் ಕನ್ನಡ ภาษาไทย 한국어  简体 繁體 have an account log in have an account remember me · forgot password new to twitter sign up foundation medicine foundationatcg tweets tweets current page  following following  followers followers  likes likes  lists lists    more likes lists unmute foundationatcg mute foundationatcg follow following unfollow blocked unblock pending cancel foundation medicine foundationatcg changing the course of cancer with molecular information httpfoundationonecomvideo  legal and privacy httpwwwfoundationmedicinecomlegal  cambridge ma foundationmedicinecom joined january   photos and videos photos and videos tweets tweets tweets current page tweets  replies media you blocked foundationatcg are you sure you want to view these tweets viewing tweets wont unblock foundationatcg yes view profile close foundation medicine followed pinned tweet foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet gauravsingalmd will discuss precisionmedicine as the key to transforming cancer care learn more httpbitlyujbna  mcconvergepictwittercomxxbjjmt  replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet give your patients w aml new treatment options talk to them about beataml® master trial using precision medicine httpbitlyuasqjn   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine retweeted llsusa‏verified account llsusa jul  more copy link to tweet embed tweet breaking new ground  adding more cancer centers we are pleased to share an update on our beataml master trial httpbitlyuzmsa pictwittercomjnrcgoeda  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet if you treat patients w aml they may be candidates for llsusa’s beataml® master trial using precision medicine httpbitlytgawxz   replies  retweet  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet read cnbc to learn how we’re accelerating cancer research w genomic data as part of cancermoonshothttpcnbcxueu   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine retweeted medcity news‏ medcitynews jul  more copy link to tweet embed tweet interested in cancer innovation head to philly by aparmarbb medcitynews httpmedcitynewscominterestedcancerinnovationheadphilly … mcconverge biotech digitalhealth  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet selecting the right biomarker for immunotherapy can impact success of clinical trialshttpscardstwittercomcardscevspviuy …  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet new findings in nejm are shedding light on using tmb vs pdl as an immunotherapy biomarker more on our blog httpbitlyvcsydg pictwittercombzpuhspfer  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet were honored to be part of joebiden’s cancermoonshot helping accelerate precision medicine research in cancer httpcnbcxunlgl pictwittercomgppdobkkrz  replies  retweets  likes reply  retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet learn how foundationact® our liquid biopsy may help guide targeted therapy in lung breast prostate cancer  more httpbitlytmdlm pictwittercomhfyycghw  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet cgp may help identify colorectal cancer patients who benefit from immunotherapy  advance personalizedmedicine httpbitlytomjd pictwittercomthluxlwz  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine retweeted constance gustke‏ cagustke jul  more copy link to tweet embed tweet joe biden’s huge push to crack the code on one of the biggest killers in americahttpcnbcxuttkpi   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jul  more copy link to tweet embed tweet research at asco is possible because of clinicaltrials learn how smarttrials™ help accelerate enrollment httpbitlyslmxg pictwittercomnlzlninnd  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine retweeted bloodpac‏ bloodpac jun  more copy link to tweet embed tweet data stewards discussing standards and model  integration astrazeneca pkuhn epicsciences novartiscancer sbgenomics foundationatcgpictwittercometkweez  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine retweeted fight crc‏ fightcrc jun  more copy link to tweet embed tweet just released you are unique so is your tumor learn more in our new resource biomarkedhttpfbmekquf   replies  retweets  likes reply retweet  retweeted  like liked thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jun  more copy link to tweet embed tweet a clinicogenomic database helps link our genomic insights w realworld outcomes learn more httpbitlysldkxt pictwittercomxnomobjnck  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jun  more copy link to tweet embed tweet read how genomic biomarkers are evolving the colorectal cancer treatment landscape in an article w oncologytimeshttpbitlytoigm   replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jun  more copy link to tweet embed tweet embed video genomic markers may help guide treatment with targeted therapy or immunotherapy get msi tmb  genomic profiling with foundationone®pictwittercomllxotnl turning the tables on cancer  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jun  more copy link to tweet embed tweet “we’re forming collaborations so we can walk up this hill together” – lauren leiman executive director bloodpac moonshotyear  replies  retweets  likes reply retweet retweeted like  liked  thanks twitter will use this to make your timeline better undo foundation medicine‏ foundationatcg jun  more copy link to tweet embed tweet foundation medicine retweeted cancer research we’re proud to share data as a member of bloodpac moonshotyear bidencancerinitiativehttpstwittercomcancerresrchstatus … foundation medicine added cancer research cancerresrch we shouldnt just be data driven we should be data informed moonshotyear  replies  retweets  likes reply retweet  retweeted  like  liked  thanks twitter will use this to make your timeline better undo foundationatcg hasnt tweeted yet back to top ↑ loading seems to be taking a while twitter may be over capacity or experiencing a momentary hiccup try again or visit twitter status for more information new to twitter sign up now to get your own personalized timeline sign up you may also like · refresh false   twitter about help center terms privacy policy cookies ads info close choose a trend location dismiss close previous next close go to a persons profile saved searches remove in this conversation verified accountprotected tweets  suggested users verified accountprotected tweets  verified accountprotected tweets  close promote this tweet close block cancel block add a location to your tweets when you tweet with a location twitter stores that location you can switch location onoff before each tweet and always have the option to delete your location history learn more turn location on not now close share location results from send close your lists close create a new list list name description under  characters optional privacy public · anyone can follow this list private · only you can access this list save list close close copy link to tweet heres the url for this tweet copy it to easily share with friends close embed this tweet embed this video add this tweet to your website by copying the code below learn more add this video to your website by copying the code below learn more hmm there was a problem reaching the server try again include parent tweet include media by embedding twitter content in your website or app you are agreeing to the twitter developer agreement and developer policy preview close why youre seeing this ad close log in to twitter remember me · forgot password dont have an account sign up » close sign up for twitter not on twitter sign up tune into the things you care about and get updates as they happen sign up have an account log in » close twoway sending and receiving short codes country code for customers of united states  any canada  any united kingdom  vodafone orange  o brazil  nextel tim haiti  digicel voila ireland  vodafone o india  bharti airtel videocon reliance indonesia  axis  telkomsel indosat xl axiata italy  wind  vodafone » see sms short codes for other countries close confirmation close   close skip all welcome home this timeline is where you’ll spend most of your time getting instant updates about what matters to you tweets not working for you hover over the profile pic and click the following button to unfollow any account say a lot with a little when you see a tweet you love tap the heart — it lets the person who wrote it know you shared the love spread the word the fastest way to share someone else’s tweet with your followers is with a retweet tap the icon to send it instantly join the conversation add your thoughts about any tweet with a reply find a topic you’re passionate about and jump right in learn the latest get instant insight into what people are talking about now get more of what you love follow more accounts to get instant updates about topics you care about find whats happening see the latest conversations about any topic instantly never miss a moment catch up instantly on the best stories happening as they unfold back next next tweet from user foundation medicine inc fmio company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile foundation medicine inc fmio related topics stocksstock screenerhealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse fmio on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description foundation medicine inc incorporated on november   is a molecular information company the company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies the company is engaged in the business of delivering molecular information about cancer to its customers the companys platform includes various methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information into clinical care its products provide genomic information about each patients individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies its suite of clinical molecular information products includes foundationone which is used for solid tumors foundationone heme which is used for bloodbased cancers or hematologic malignancies including leukemia lymphoma myeloma pediatric cancers and advanced sarcoma foundationact assay for circulating tumor dna which is a bloodbased liquid biopsy assay that evaluates circulating tumor deoxyribonucleic acid ctdna and foundationfocus cdxbrca which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with rubraca rucaparibas of december   foundationone assessed  biologically relevant cancer genes for all classes of genomic alterations with sensitivity and specificity the companys foundationice is an online interactive cancer explorer and allows physicians to access the genomic information identified by its products along with information about the reported genomic alterations associated therapies and clinical trials foundationice presents genomic information in an interface that links directly into publicly available databases such as pubmed and clinicaltrialsgov to provide additional information relevant to a patients identified genomic alterations the companys foundationcore is its knowledgebase that includes genomic data medical and scientific literature clinical trial information and a small but growing amount of clinical outcome information foundationcore powers foundationice enabling oncologists and pathologists in clinical practice to utilize this aggregated data set to collaborate and share treatment choices response rates and other clinical information in the health insurance portability and accountability act hipaacompliant manner each foundationone foundationone heme and foundationact analysis consists of three parts specimen preparation sequencing and data analysis and reportingthe company competes with bioreference laboratories inc laboratory corporation of america holdings quest diagnostics incorporated caris life sciences guardant health paradigm neogenomics laboratories abbott laboratories qiagen nv sequenom inc genomic health inc myriad genetics inc illumina thermo fisher scientific inc biocept exosome diagnostics inivata personal genome diagnostics and roche diagnostics » full overview of fmio company address foundation medicine inc  nd stcambridge   ma    p f  company web links home page officers  directors name compensation michael pellini  steven kafka  troy cox  jason ryan  robert hesslein  » more officers  directors foundation medicine inc news briefkura oncology ‍enters into collaboration agreement with foundation medicine ​ jul   brieffoundation medicine q loss per share  feb   briefdiscovery group i llc reports  pct stake in foundation medicine as of jan   sec filing jan   » more fmio news related topics stocksstock screenerhealthcarebiotechnology  medical research press releases  foundation medicine skip to content foundation medicine log in menu investors  press press releases jump to a page investor relations corporate governance sec filings events  presentations investor faqs stock information analyst coverage press releases quarterly results email alerts executive team filter releases year all years         sort by date descending date ascending update foundation medicine announces timing for second quarter  financial results and conference call july      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys second quarter ended june   will be released on tuesday august   the management team will host a conference call on tuesday august   at  pm et t read more asco and foundation medicine announce collaboration to help research sites identify potential participants for the targeted agent and profiling utilization tapur study june      pdf  kb alexandria va  cambridge massbusiness wire the american society of clinical oncology inc asco and foundation medicine nasdaq fmi today announced entry into an agreement to create efficiencies for research sites participating in ascos tapur™ study in identifying potential participants for  read more foundation medicine to identify patients eligible for national cancer institutes ncimatch molecular analysis for therapy choice study june      pdf  kb cambridge massbusiness wire foundation medicine nasdaq fmi today announced a collaboration with the national cancer institute nci and ecogacrin cancer research group ecogacrin for their precision medicine cancer trial ncimolecular analysis for therapy choice ncimatch or eay this ongoing  read more foundation medicine to present at upcoming investor conferences june      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences goldman sachs annual healthcare conference on tuesday june    read more foundation medicine and its collaborators to present new data at asco  supporting the integration of comprehensive genomic profiling cgp in personalized clinical care in oncology may      pdf  kb new data including content from two oral presentations continues to validate the clinical value of molecular information from cgp in guiding treatment towards targeted therapy immunotherapy and clinical trials cambridge massbusiness wire foundation medicine  read more foundation medicine announces  first quarter results and recent highlights may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its first quarter ended march   results and business highlights for the quarter included reported  clinical tests in the first quarter  read more foundation medicine announces timing for first quarter  financial results and conference call april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys first quarter ended march   will be released on tuesday may   the management team will host a conference call on tuesday may   at  pm et to disc read more bristolmyers squibb enters collaboration to leverage foundation medicines molecular information platform to identify predictive biomarkers across multiple tumor types and immunotherapy agents march      pdf  kb new york  cambridge massbusiness wire bristolmyers squibb company nysebmy and foundation medicine nasdaqfmi today announced a collaboration that leverages foundation medicines comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as tu read more foundation medicine receives medicare payment in nonsmall cell lung cancer under a local coverage determination for foundationone® the companys comprehensive genomic profiling assay march      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it has received payment from palmetto gba the companys medicare administrative contractor mac in north carolina for its foundationone comprehensive genomic profiling assay when used in the clinical course read more foundation medicine to present at cowen and companys th annual healthcare conference february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at cowen  companys th annual healthcare conference on monday march   at  pm et in boston a live listenonly we read more foundation medicine announces  fourth quarter and yearend results recent highlights and  outlook february      pdf  kb cambridge massbusiness wire foundation medicine nasdaqfmi today reported financial and operational results for the fourth quarter and year ended december   highlights for the quarter and year included fourth quarter revenue of  million  yearovery read more foundation medicine announces timing for fourth quarter and yearend  financial results and conference call february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys fourth quarter and year ended december   will be released on wednesday february   the management team will host a conference call on wednesday february   read more foundation medicine reports preliminary  results january      pdf  kb achieves total revenue of approximately  million a  year over year increase reports  clinical tests in  a  year over year increase cambridge massbusiness wire foundation medicine nasdaqfmi today announced preliminary unaudited total read more foundation medicine announces executive leadership transition january      pdf  kb proven biopharma executive and commercial leader troy cox named as chief executive officer to succeed michael pellini md dr pellini named chairman of the companys board of directors cambridge massbusiness wire foundation medicine inc nasdaqfmi tod read more foundation medicine to present at the th annual jp morgan healthcare conference january      pdf  kb cambridge massbusiness wire foundation medicine nasdaqfmi today announced that michael j pellini md chief executive officer is scheduled to present at the th annual jp morgan healthcare conference on tuesday january   at  am pst in san francisco  read more foundation medicine receives fda approval of foundationfocus™ cdxbrca as a companion diagnostic for rubraca™ rucaparib for the treatment of women with ovarian cancer december      pdf  kb first and only companion diagnostic to detect tumor brca alterations potentially increasing the number of women who are eligible for rubraca rucaparib therapy fda approval of foundationfocus cdxbrca marks important progress towards foundation medicines development of a compre read more flatiron health and foundation medicine unveil powerful oncology information resource to advance precision medicine november      pdf  kb new york  cambridge massbusiness wire flatiron health and foundation medicine inc nasdaqfmi today announced the launch of a clinicogenomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted therapeutics and immunotherapies t read more foundation medicine announces  third quarter results and recent highlights november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its third quarter ended september   highlights for the quarter included achieved third quarter revenue of  million  yearoveryear  read more foundation medicine and sarah cannon collaborate to advance personalized medicine for patients with cancer october      pdf  kb molecular informationbased collaboration focuses on integrating comprehensive genomic profiling into clinical trials to enable patient access to targeted therapeutics cambridge mass  nashville tennbusiness wire foundation medicine inc nasdaqfmi and sarah cannon rese read more foundation medicine adds life sciences leader michael r dougherty to its board of directors october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the election of michael r dougherty to its board of directors mr dougherty brings more than  years of executive and operational leadership to his role as an independent director at foundation medicine mr dou read more foundation medicine announces timing for third quarter  financial results and conference call october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys third quarter ended september   will be released on wednesday november   the management team will host a conference call on wednesday november   at  read more foundation medicine to present at the morgan stanley global healthcare conference september      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the morgan stanley global healthcare conference on monday september   at  pm et in new york city a live listen read more foundation medicine adds new immunotherapy features to its marketleading products august      pdf  kb  first fullyintegrated and validated assessments of tumor mutational burden tmb and microsatellite instability msi provide oncologists with a single testing solution to guide personalized immunotherapybased treatment plans  cambridge massbusiness wire foundation  read more foundation medicine announces  second quarter results and recent highlights august      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its second quarter ended june   highlights for the quarter included achieved second quarter revenue of  million  yearoveryear  read more foundationone® accepted by fda and cms for parallel review and fda expedited access pathway august      pdf  kb parallel review of foundationone if successful could result in fda approval of the first pancancer comprehensive genomic profiling assay incorporating a range of companion diagnostics concurrently with a cms national coverage determination cambridge massbusiness  read more foundation medicine announces timing for second quarter  financial results and conference call july      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys second quarter ended june   will be released on tuesday august   the management team will host a conference call on tuesday august   at  pm et  read more foundation medicine announces release of molecular information from foundationcore™ to the national cancer institute in support of the national cancer moonshot and precision medicine initiatives june      pdf  kb data will be released to the ncis genomic data commons portal to advance precision medicine and drive improvements in cancer care cambridge massbusiness wire foundation medicine inc nasdaqfmi announced today that the company will release approximately  read more new data from foundation medicine and collaborators supports use of comprehensive genomic profiling to inform therapeutic choices in advanced breast cancer june      pdf  kb genomic information revealed by foundationone® leads to  physiciandirected change in therapeutic treatment selection biomarkers of immune checkpoint inhibitors identify opportunity for clinical response to immunotherapies cambridge massbusiness w read more data from a study utilizing foundationone® heme indicates ageassociated genomic profiles in acute myeloid leukemia june      pdf  kb study validates foundationone hemes  concordance with conventional genomic testing and ability to identify additional mutations not captured by other molecular assays data presented by foundation medicine and collaborators at the  asco annual meeting further propels the advancement of pre read more foundation medicine presents new data at asco  demonstrating that foundationone® may help predict response to cancer immunotherapy across a variety of advanced cancers june      pdf  kb molecular information on tumor mutational burden supports improved outcomes and drives care efficiencies cambridge mass  chicagobusiness wire foundation medicine inc nasdaqfmi and it collaborators presented data showing that higher tumor mutational burden as estimated read more foundationone® identifies patients with advanced lung cancer likely to respond or develop resistance to certain ret inhibitor therapies june      pdf  kb data underscore the value of molecular information to enable informed therapeutic choices improved outcomes and efficient clinical care cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced new critical genomics data at the american society of clinical o read more foundation medicine and astrazeneca enter strategic collaboration for lynparza companion diagnostic assay june      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi and astrazeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for lynparza olaparib to support its global development program the companion diagnostic will enab read more foundation medicine to present at the goldman sachs annual healthcare conference june      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the goldman sachs annual healthcare conference on wednesday june   at  pm pt in rancho palos verdes california  read more foundation medicine announces presentations at asco may      pdf  kb data supports comprehensive genomic profiling for identifying therapeutic treatment options and determining predictors of therapeutic response across broad cancer types cambridge mass  chicagobusiness wire foundation medicine inc nasdaqfmi today ann read more foundation medicine receives patent covering fundamental methods in comprehensive genomic analysis in cancer may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the us patent and trademark office has issued us patent number  entitled optimization of multigene analysis of tumor samples the patent which is assigned to foundation medicine includes fun read more foundation medicine announces  first quarter results and recent highlights may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its first quarter ended march   highlights for the quarter included achieved first quarter revenue of  million  yearoveryear  read more foundation medicine announces commercial launch of liquid biopsy assay foundationact™ may      pdf  kb  bloodbased genomic profiling assay provides new option for cancer patients who are not candidates for tissue biopsy  cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the launch of foundationact assay for circulating tumor dna an analytically read more foundation medicine and astrazeneca collaborate to develop companion diagnostic assays in oncology may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced an agreement with astrazeneca to develop companion diagnostic assays to facilitate personalized medicine in oncology by identifying patients most likely to benefit from medicines within astrazenecas oncology pipel read more foundation medicine to present at upcoming investor conferences april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences bank of america merrill lynch  healthcare conference on tuesday  read more foundation medicines molecular information supports discovery of precision therapeutics for pediatric cancers april      pdf  kb  data from a comprehensive genomic dataset of  pediatric cancers presented today in a latebreaking poster session at the aacr annual meeting  cambridge massbusiness wire foundation medicine inc nasdaqfmi today presented new data from more than  ped read more foundation medicine announces timing for first quarter  financial results and conference call april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys first quarter ended march   will be released on tuesday may   the management team will host a conference call discussing the companys financial results and  read more new data with foundationone® supports clinical utility and improved outcomes from molecularly matching nonsmall cell lung cancer patients to targeted therapy march      pdf  kb data published in peerreviewed journals provide further evidence of the ability of comprehensive genomic profiling to find clinically relevant alterations often missed by hotspot assays cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the p read more foundation medicine and memorial sloan kettering publish validation data for foundationone® heme in the journal blood march      pdf  kb new data demonstrate accuracy and clinical application of comprehensive genomic profiling to improve the diagnosis and treatment of a wide range of hematologic malignancies cambridge mass  new yorkbusiness wire foundation medicine inc nasdaqfmi and memorial sl read more foundation medicine announces presentations at the aacr annual meeting  march      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present two minisymposium presentations and seven posters at the american association for cancer research aacr annual meeting  taking place april  in new orle read more foundation medicine presents new data at the  uscap annual meeting underscoring importance of comprehensive genomic profiling in cancer care march      pdf  kb latest data demonstrate the clinical utility of foundationone® in brain and breast cancers to complement standard pathology practices in improving oncology patient outcomes with targeted therapy cambridge massbusiness wire foundation medicine inc nasdaqfmi and its  read more foundation medicine to present at cowen and companys th annual healthcare conference february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at cowen  companys th annual healthcare conference on monday march   at  pm et in boston a live listenonly we read more foundation medicine announces firstever public release of broad pediatric data from foundationcore™ to accelerate the development of precision medicine strategies for pediatric cancers february      pdf  kb data release announced today at white house precision medicine initiative summit cambridge mass  washingtonbusiness wire foundation medicine inc nasdaqfmi today announced that the company will release to the public molecular profiles of pediatric cancers currently  read more foundation medicine announces  fourth quarter and yearend results recent highlights and  outlook february      pdf  kb cambridge massbusiness wire foundation medicine nasdaq fmi today reported financial and operational results for the fourth quarter and year ended december   highlights for the quarter and year included fourth quarter revenue of  million  yearover read more foundation medicine announces timing for fourth quarter and yearend  financial results and conference call february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys fourth quarter and year ended december   will be released on tuesday february   the management team will host a conference call discussing the companys fin read more foundation medicine to present at the leerink global healthcare conference february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the leerink global healthcare conference on thursday february   at  pm et in new york city a live listenonly read more foundation medicine horizon healthcare services inc and cota collaborate to demonstrate the benefits of a precision medicine treatment approach for patients with metastatic nonsmall cell lung cancer january      pdf  kb study aims to demonstrate the clinical utility of and cost savings achieved by integrating comprehensive genomic profiling with foundationone® into clinical pathways cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced a threeway  read more foundation medicine reports preliminary  results and provides  business outlook including commercial launch of its ctdna assay january      pdf  kb achieves revenue of approximately  million a  year over year increase reports approximately  clinical tests in  a  year over year increase cambridge massbusiness wire foundation medicine nasdaqfmi today announced preliminary read more foundation medicine announces presentations at the  genitourinary cancers symposium january      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present seven poster presentations at the  genitourinary cancers symposium taking place january   in san francisco the companys mol read more foundation medicine to present at the th annual jp morgan healthcare conference january      pdf  kb cambridge massbusiness wire foundation medicine today announced that michael j pellini md chief executive officer is scheduled to present at the th annual jp morgan healthcare conference on wednesday january   at  am pst in san francisco a live l read more foundation medicine announces national agreement with unitedhealthcare for foundationone® in metastatic nonsmall cell lung cancer december      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it has signed a national agreement for foundationone® a comprehensive genomic profiling assay for solid tumors with unitedhealthcare one of the nations largest private payers the agreement which bec read more foundation medicine and mirati therapeutics collaborate to develop a companion diagnostic for glesatinib mgcd in nonsmall cell lung cancer nsclc december      pdf  kb cambridge mass and san diego  dec    foundation medicine inc nasdaq fmi and mirati therapeutics inc mirati nasdaq mrtx a targeted oncology company focusing on genetic and epigenetic drivers of cancer today announced that they have entered into a collaboration for the development of a companion diagnostic test for glesa read more foundation medicine announces presentations at the  san antonio breast cancer symposium december      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present  poster presentations at the  san antonio breast cancer symposium sabcs annual meeting taking place december   in san antonio texas  read more foundation medicine to present at the goldman sachs smid cap growth conference november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the goldman sachs smid cap growth conference on thursday november   at  am et in new york city a live listen read more foundation medicine and collaborators to present new clinical data supporting comprehensive genomic profiling in advanced sarcomas and hematologic malignancies with foundationone® heme november      pdf  kb data to be presented at the th annual meeting of the american society of hematology cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present three oral and four poster presentations at t read more foundation medicine announces  third quarter results and recent highlights november      pdf  kb yearoveryear third quarter revenues grow  foundationcore™ expands to approximately  patient cases ctdna product launch on track cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its third  read more foundation medicine announces roche pharmaceuticals israel ltd to commence commercial activities in support of its molecular information products in oncology november      pdf  kb  israel selected as the first exus launch country for foundation medicines products  cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that f hoffmann laroches affiliate in israel roche pharmaceuticals israel ltd will c read more foundation medicine announces timing for third quarter  financial results and conference call october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys third quarter ended september   will be released on tuesday november   the management team will host a conference call discussing the companys financial res read more foundation medicine launches precision medicine exchange consortium™ pmec to advance the integration of molecular information in clinical oncology and accelerate adoption of precision care september      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the launch of its precision medicine partner program precision medicine exchange consortium™ pmec to facilitate data exchange advance research and support education and applications of precision medicin read more foundation medicine expands molecular information decision support offerings with genekit™ a genomic solutions portal for pathologists september      pdf  kb powered by foundationcore™ genekit enables unmatched interpretation analysis and reporting of genomic data into clinical practice cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the expansion of its suite of molecular informationba read more foundation medicine to present at morgan stanley global healthcare conference september      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the morgan stanley global healthcare conference on wednesday september   at  am edt in new york city a live li read more foundation medicine to webcast investor  analyst day august      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it will provide a live video webcast and conference call for its investor  analyst day on september   at the event members of the foundation medicine management team will discuss the companys fivey read more foundation medicine to present at wedbush pacgrow healthcare conference august      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the wedbush pacgrow healthcare conference on tuesday august   at  pm edt in new york city a live listenonly w read more foundation medicine announces  second quarter results and recent highlights july      pdf  kb yearoveryear revenues grow  foundationcore™ expands to more than  patient cases guidance updated for  cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its second quarter ended june  read more foundation medicine initiates multicenter clinical study evaluating its circulating tumor dna ctdna assay in multiple tumor types july      pdf  kb study aims to validate assay and identify appropriate clinical subpopulations for commercial use cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the initiation of a largescale multicenter prospective clinical study to validate its  read more foundation medicine announces timing for second quarter  financial results and conference call july      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys second quarter ended june   will be released on wednesday july   the management team will host a conference call discussing the companys financial results  read more ims health and foundation medicine announce collaboration to optimize targeting of precision therapies in oncology june      pdf  kb extends and integrates ims health realworld evidence platform with foundationcore for outcomes insights commercialization strategies danbury conn  cambridge massbusiness wire ims health nyseims and foundation medicine inc nasdaqfmi today announced a collaboration to adva read more foundation medicine to present at upcoming investor conferences june      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences the goldman sachs global healthcare conference on tuesday june   read more foundation medicine identifies patients likely to respond to certain met inhibitor targeted therapies durable responses in nonsmall cell lung cancer nsclc presented at asco annual meeting june      pdf  kb data support role of met exon  alterations as a viable therapeutic target and highlight need for reimbursement of comprehensive genomic profiling in leading cancer killer cambridge mass  chicagobusiness wire foundation medicine inc nasdaqfmi today announced new data  read more comprehensive genomic profiling with foundationone® guides targeted therapeutic choices and clinical responses in challenging biliary tract cancers may      pdf  kb cambridge mass  chicagobusiness wire foundation medicine inc nasdaqfmi today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with foundationone® into clinical oncology care for the treatment of biliary  read more new data demonstrate improved patient outcomes with matched cancer therapy informed by comprehensive genomic profiling with foundationone® may      pdf  kb study aims to advance precision medicine through the integration of molecular information into clinical cancer care data presented by foundation medicine and collaborators at the  asco annual meeting cambridge mass  chicagobusiness wire foundation  read more foundation medicine and collaborators to present data in  oral and poster presentations at the  asco annual meeting may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present  oral and poster presentations at the  american society for clinical oncology asco annual meeting taking place may   june   in chicago  read more foundation medicines comprehensive genomic profile informs therapeutic choices and leads to promising outcomes in pediatric patients with gliomas may      pdf  kb new clinical data presented at the rd biennial pediatric neurooncology basic and translational research conference cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced new data demonstrating that its comprehensive genomic profiling assay foun read more foundation medicine announces  first quarter results and recent highlights may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for its first quarter ended march   highlights for the quarter included  clinical tests reported in the first quarter  yearoveryear  read more foundation medicine to present at upcoming investor conferences may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences michael j pellini md chief executive officer will present at the  read more foundation medicine and collaborators to present new data in  oral and poster presentations at the aacr annual meeting april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its collaborators will present  oral and poster presentations at the american association for cancer research aacr annual meeting  taking place april   at the pennsylvania con read more foundation medicine announces its collaboration with the national cancer institute on exceptional responders initiative april      pdf  kb firstofitskind exploratory study investigates unique molecular indicators of tumors associated with exceptional treatment responses to drug therapies in patients with cancer cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it has ent read more foundation medicine announces timing for first quarter  financial results and conference call april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys first quarter ended march   will be released on monday may   the management team will host a conference call discussing the companys financial results and r read more foundation medicine and roche complete strategic transaction to advance molecular information and precision medicine in oncology april      pdf  kb transaction closing results in m in gross proceeds for foundation medicine and commences rd and commercial agreements with roche roche gains minority board representation and becomes majority shareholder in foundation medicine cambridge massbusiness  read more foundation medicine stockholders approve pending roche transaction at special meeting of stockholders april      pdf  kb  pending roche tender offer scheduled to expire at the end of the day on monday april    cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that its stockholders approved each proposal presented at the special meetin read more foundation medicine and collaborators to present new data in  oral and poster presentations at the  uscap annual meeting march      pdf  kb data underscore benefits of leveraging comprehensive genomic profiling to complement standard pathology practices for improving patient outcomes with targeted therapy cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company and its  read more foundation medicine announces executive promotions and expanded leadership team to complement global growth initiatives march      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced four executive promotions and a new leadership appointment to support and accelerate the companys united states and global commercial and operational growth plans steven kafka read more foundation medicine announces proposed changes to its board of directors in connection with the pending roche transaction march      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced proposed changes to its board of directors in connection with its pending strategic collaboration with roche under the terms of the agreement with roche foundation medicines board will i read more foundation medicine to present at upcoming investor conferences february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences michael j pellini md president and chief executive officer will  read more foundation medicine announces  fourth quarter and yearend results recent highlights and  outlook february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for the fourth quarter and year ended december   highlights for the quarter and year include  clinical tests reported in the fourth quarter  read more foundation medicine and h biomedicine announce collaboration to develop precision therapies for cancer february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi and h biomedicine inc today announced a multiyear collaboration for the discovery and development of precision medicines in oncology the collaboration marries foundation medicines comprehensive genomic knowledgebase  read more foundation medicine to present new clinical data on clinical applications of foundationone® at the th annual advances in genome biology and technology meeting february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that new clinical data on the application of foundationone® will be presented during two podium presentations and one poster session at the th annual advances in genome biology and technology agbt  read more new data from foundationone® demonstrates genomic basis for potential new routes to therapy and improved outcomes for individuals with cancers of unknown primary february      pdf  kb retrospective study using foundationone identifies clinically relevant genomic alterations in  of cup cases data published in inaugural issue of jama oncology cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that new data  read more foundation medicine to present at the leerink global healthcare conference february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced steven kafka phd chief operating officer is scheduled to present at the leerink global healthcare conference on wednesday february   at  pm est in new york city a live read more foundation medicine announces timing for fourth quarter and yearend  financial results and conference call february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys fourth quarter and year ended december   will be released on tuesday february   the management team will host a conference call discussing the companys fin read more foundation medicine enters a broad strategic collaboration with roche in the field of molecular information in oncology january      pdf  kb —collaboration leverages both companies strengths to advance the progress of personalized treatments for patients with cancer— roche to acquire a majority interest in foundation medicine of up to  on a fully diluted basis through a tender and acquisition of newly  read more foundation medicine reports preliminary  results january      pdf  kb achieves revenue of approximately  million and reports more than  clinical tests in  cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced preliminary unaudited total revenue of approximately  million in the fourth quarter of  read more foundationone® identifies high frequency of clinically relevant genomic alterations ga previously missed by conventional genomic tests enabling successful targeted treatment in patients with nonsmall cell lung cancer january      pdf  kb  of patients found to have gas tied to available therapeutic options data published in clinical cancer research cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that foundationone® the companys flagship com read more foundation medicine and collaborators to present new clinical data on the application of foundationone® at the  gastrointestinal cancers symposium january      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that new clinical data on the application of foundationone® will be presented during two oral presentations and one poster session at the  gastrointestinal cancers symposium taking place january  read more foundation medicine launches ice  its new version of interactive cancer explorer featuring patientmatch january      pdf  kb ice  enables physicians to more effectively leverage comprehensive genomic profiling in their practices cambridge massbusiness wire foundation medicine inc nasdaqfmi announced the recent launch of ice ™ the newest version of its interactive cancer expl read more foundation medicine to present at the jp morgan healthcare conference january      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced michael j pellini md president and chief executive officer is scheduled to present at the rd annual jp morgan healthcare conference on wednesday january   at  am pst in san francisco ca  read more foundation medicine to be added to nasdaq biotechnology index december      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the company will be added to the nasdaq biotechnology index nasdaq nbi effective prior to the market open on monday december   the nasdaq biotechnology index is designed to track t read more foundationone® identifies clinically relevant genomic alterations in patients with advanced breast cancers december      pdf  kb data presented at  san antonio breast cancer symposium highlight potential for comprehensive genomic profiling approach to inform patient treatment options cambridge mass  san antoniobusiness wire foundation medicine inc nasdaqfmi today announced new data further  read more new clinical data supports the use of foundationone® heme to enable informed treatment decisions in a wide range of hematologic malignancies december      pdf  kb comprehensive genomic profiling data presented in collaboration with memorial sloan kettering cancer center at american society of hematology annual meeting cambridge mass  san franciscobusiness wire foundation medicine inc nasdaqfmi today announced new data demonstrat read more treatment for relapsed multiple myeloma patients guided by foundationone® heme results in promising clinical activity december      pdf  kb new clinical data on foundation medicines comprehensive genomic profile presented at american society of hematology annual meeting cambridge mass  san franciscobusiness wire foundation medicine inc nasdaqfmi today announced new data demonstrating that its comprehensiv read more foundation medicine and collaborators to present new clinical data on the application of foundationone® in breast cancer at the  san antonio breast cancer symposium december      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that eight abstracts highlighting new clinical data on the application of foundationone® in patients with breast cancer will be presented at the th annual san antonio breast cancer symposium sabcs taking p read more foundation medicine appoints david j daly as chief commercial officer december      pdf  kb clinical oncology diagnostics leader tapped to lead ongoing commercial growth and geographic expansion cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the appointment of david j daly to the role of chief commercial officer mr daly brings read more foundation medicine and flatiron health collaborate to develop firstinclass data platform to accelerate precision medicine for cancer december      pdf  kb joint effort to create unique genomic and clinical outcomes information solution to inform and accelerate development of targeted therapies to advance patient care cambridge mass  new yorkbusiness wire foundation medicine inc nasdaqfmi and flatiron health toda read more foundation medicine to present at the piper jaffray healthcare conference november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced steven j kafka phd chief operating officer is scheduled to present at the piper jaffray healthcare conference on wednesday december   at  pm et in new york city a liv read more foundation medicines novel companion diagnostic test developed in collaboration with clovis oncology identifies expanded subgroup of cancer patients with the potential to respond to clovis oncologys parp inhibitor rucaparib november      pdf  kb interim phase  data presented at eortcnciaacr symposium cambridge mass  barcelona spainbusiness wire foundation medicine inc nasdaq fmi today announced the presentation of new data from its ongoing collaboration with clovis oncology nasdaq clvs to develop a nove read more foundation medicine to present at upcoming investor conferences november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences michael j pellini md president and chief executive officer will  read more the robert h lurie comprehensive cancer center of northwestern university and the northwestern medicine developmental therapeutics institute partner with foundation medicine to launch innovative clinical translation program november      pdf  kb cambridge mass  chicagobusiness wire the robert h lurie comprehensive cancer center of northwestern university lurie cancer center and the northwestern medicine developmental therapeutics institute nmdti today announced the initiation of a new clinical translation program with foundation me read more foundation medicine and collaborators to present new clinical data on foundationone® heme at the american society of hematology annual meeting november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that  abstracts highlighting new clinical data on foundationone® heme will be presented at the th american society of hematology ash annual meeting and exposition taking place december   at the  read more foundation medicine announces  third quarter results and recent highlights november      pdf  kb continued commercial execution reimbursement progress and updated guidance cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for the quarter ended september     read more foundation medicine signs data partnership with cancer outcomes tracking and analysis cota inc to inform valuebased cancer treatment november      pdf  kb cota will expand foundation medicines molecular information knowledgebase with longitudinal clinical outcomes and cost of care data and analytics cambridge mass  hackensack njbusiness wire foundation medicine inc nasdaq fmi and cota inc today announced an agreeme read more foundation medicine partners with emergingmed to offer clinical trial navigation services for physicians and patients november      pdf  kb foundation medicine facilitates patient access to clinical trials by offering personalized guidance through the selection and enrollment process cambridge mass  new yorkbusiness wire foundation medicine inc nasdaq fmi and emergingmed today announced a partnership to of read more foundation medicine and wuxi pharmatech announce strategic collaboration to offer bestinclass comprehensive genomic profiling in china october      pdf  kb cambridge mass and shanghai oct   prnewswire  foundation medicine inc nasdaqfmi and wuxi pharmatech cayman inc nysewx today announced a collaboration to offer foundation medicines comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in china under the terms of the collaboratio read more priority health is first health plan to cover foundationone® and foundationone® heme to enhance precision cancer treatment october      pdf  kb coverage for foundation medicines comprehensive cancer genomic profiles now available to members of michiganbased priority health cambridge mass  grand rapids michbusiness wire foundation medicine inc nasdaqfmi and priority health today announced an agreement to en read more foundation medicine announces timing for third quarter  financial results and conference call october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys third quarter ended september   will be released on wednesday november   the management team will host a conference call discussing the companys financial r read more foundation medicine to present at the morgan stanley global healthcare conference september      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that michael pellini md president and chief executive officer is scheduled to present at the morgan stanley global healthcare conference on wednesday september   at  am et in new york city  read more foundation medicine announces  second quarter results and recent highlights august      pdf  kb continued strength in clinical test volume and revenue growth cambridge massbusiness wire foundation medicine inc nasdaqfmi today reported financial and operating results for the quarter ended june    clinical tests reported  read more foundation medicine to present at the wedbush  life sciences conference august      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that jason ryan senior vice president finance is scheduled to present at the wedbush  life sciences conference on wednesday august   at  pm et in new york city a li read more foundation medicine appoints lisa ricciardi senior vice president corporate and business development august      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the appointment of life sciences executive lisa ricciardi to the newly created position of senior vice president corporate and business development in this role ms ricciardi will be responsible for overseeing t read more foundation medicine releases enhanced version of foundationone® july      pdf  kb companys flagship comprehensive genomic profile continues to deliver leadingedge innovation to patients with cancer cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced the launch of an updated foundationone® incorporating seve read more foundation medicine partners with the addario lung cancer medical institute for innovative prospective study linking the genomic drivers of lung cancer in young adults with treatment options july      pdf  kb newly launched international study aims to better inform treatment options for lung cancer in a unique underserved population cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that it has partnered with the addario lung cancer medical institute alc read more foundation medicine receives approvals from new york state department of health for foundationone® and foundationone heme® july      pdf  kb these products are the first fully informative genomic profiles to be validated by new york states regulatory review process cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it has received final approval from the new york state depart read more foundation medicine announces timing for second quarter  financial results and conference call july      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys second quarter ended june   will be released on tuesday august   the management team will host a conference call discussing the companys financial results  read more foundation medicine offers foundationone® careline to provide personalized assistance to cancer patients seeking access to targeted therapies june      pdf  kb partnership with patient advocate foundation aims to expand access for patients facing barriers to prescribed treatments and related healthcare services cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that it has partnered with patient adv read more groundbreaking collaborative clinical trial launched june      pdf  kb bethesda md june   prnewswire  a unique publicprivate collaboration among the national cancer institute nci part of the national institutes of health swog cancer research friends of cancer research friends the foundation for the national institutes of health fnih five pharmaceutical companies amgen genentech pfizer ast read more foundation medicine to present at upcoming investor conferences june      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences michael j pellini md president and chief executive officer will  read more foundationone® identifies clinically relevant alterations in adolescent and young adult solid tumors june      pdf  kb analysis of solid tumors in  patients reveals genomic alterations distinct to a commonly overlooked population that may lead to more effective treatment decisions cambridge mass  chicagobusiness wire foundation medicine inc nasdaq fmi today announced results from a  read more foundation medicine identifies actionable genomic alterations in pediatric cancers new clinical data to be presented at  asco annual meeting june      pdf  kb data demonstrate accurate genomic profiling may inform targeted therapeutic options for pediatric patients with cancer foundationone® heme now available for profiling cancer in children cambridge mass  chicagobusiness wire foundation medicine inc nasdaq fmi today read more foundation medicine announces initial data demonstrating clinical utility of foundationone® in advanced solid tumors clinical data to be presented at  asco annual meeting may      pdf  kb physicians altered therapy decisions for  percent of patients with a range of tumor types based on foundationone test results cambridge mass  chicagobusiness wire foundation medicine inc nasdaq fmi today announced new data demonstrating that the foundationone® fully info read more foundation medicine and collaborators to present new clinical data on foundationone® and foundationone heme at the  asco annual meeting may      pdf  kb data describe clinical application of foundationone across multiple tumor types cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that  abstracts highlighting new clinical data on foundationone® and foundationone heme will be  read more foundation medicine announces key developments in international commercialization efforts may      pdf  kb company receives ce mark approval for foundationone® adds new distribution partner and appoints experienced executive to lead international expansion cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that it has obtained a ce  read more foundation medicine announces  first quarter results and recent highlights may      pdf  kb company drives  growth in clinical tests reported compared to  fourth quarter cambridge massbusiness wire foundation medicine inc nasdaq fmi today reported total revenue of  million in the first quarter of  compared to  million in the fourth quarter read more foundation medicine to present at the bank of america merrill lynch  healthcare conference may      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that michael j pellini md president and chief executive officer is scheduled to present at the bank of america merrill lynch  healthcare conference on tuesday may   at  pm pt in las vegas read more foundation medicine announces timing for first quarter  financial results and conference call april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys first quarter ended march   will be released on wednesday may   the management team will host a conference call discussing the companys financial results and read more foundation medicine and clovis oncology expand collaboration to develop novel companion diagnostic for rucaparib in ovarian cancer april      pdf  kb companion diagnostic development builds upon regulatory strategy for foundation medicines comprehensive genomic profiling platform and differentiated clinical development strategy for clovis oncology cambridge mass  boulder colobusiness wire foundation medicine inc na read more foundation medicine announces new data highlighting foundationone™ and foundationone™ heme to be presented at the aacr annual meeting  april      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that new clinical data including additional validation for foundationone™ and foundationone™ heme will be presented at the american association of cancer research aacr annual meeting  taking place read more foundation medicine to present at upcoming investor conferences february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that members of the companys management team will present at the following upcoming investor conferences steven j kafka phd chief operating officer will present at the  read more foundation medicine announces  fourth quarter and yearend results and recent highlights february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced total revenue of  million in the  fourth quarter compared to  million in the  third quarter the company reported  clinical tests in the  fourth quarter up from  in the  third quarter to read more foundation medicine and collaborators identify high incidence of genomic alterations linked to targeted therapies in liver cancer data published in the oncologist february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced the results of a new study demonstrating that foundationone™ identified genomic alterations linked to targeted therapies or clinical trials in   of patients with intrahepatic cholangiocarcinoma ic read more foundation medicine announces timing for fourth quarter and yearend  financial results and conference call february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that financial results for the companys fourth quarter and year ended december   will be released on tuesday february   the management team will host a conference call discussing the companys fina read more foundation medicine to present at the  leerink global healthcare conference february      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that michael j pellini md president and chief executive officer is scheduled to present at the  leerink global healthcare conference on wednesday february   at  pm et in new york city  read more foundation medicine reports preliminary  results and provides  guidance january      pdf  kb achieves revenue of approximately  million and reports over  clinical tests in  cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced preliminary unaudited total revenue of approximately  million for the year ended december   read more foundation medicine discovers high incidence of clinically actionable erbb her alterations in aggressive form of bladder cancer data published in clinical cancer research january      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced the discovery of a high incidence of erbb her extracellular domain alterations in patients with micropapillary urothelial carcinoma mpuc a particularly aggressive form of urinary bladder cancer using  read more foundation medicine extends and expands collaboration to provide molecular information and genomic profiling for clinical oncology programs january      pdf  kb cambridge massbusiness wire foundation medicine today announced it has extended and expanded its ongoing collaboration with novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of novartis clinical oncology programs the collaboration will now read more foundation medicine to present at the nd annual jp morgan healthcare conference january      pdf  kb cambridge massbusiness wire foundation medicine today announced that michael j pellini md president and chief executive officer is scheduled to present at the nd annual jp morgan healthcare conference on wednesday january   at  am pst in san francisco  read more novel and previously reported genomic alterations identified in clinical multiple myeloma cases using foundationone™ heme december      pdf  kb comprehensive genomic profiling may lead to new therapeutic options for patients data presented at american society of hematology annual meeting cambridge massbusiness wire foundation medicine today announced new data from a pilot study demonstrating that its fully read more foundationone™ heme enables identification of genomic alterations not identified by conventional methods across hematologic malignancies december      pdf  kb comprehensive genomic profiling utilizing dna and rna sequencing may expand treatment options for patients data presented at american society of hematology annual meeting cambridge massbusiness wire foundation medicine today announced new data demonstrating that its fully  read more foundation medicine launches foundationone™ heme developed in collaboration with memorial sloankettering cancer center december      pdf  kb foundationone heme foundation medicines second clinical product is a fully informative genomic profile for hematologic malignancies sarcomas and pediatric cancers cambridge mass  new yorkbusiness wire foundation medicine announced today the launch of its second clinical read more new data highlighting foundation medicines second clinical product to be presented at american society of hematology annual meeting november      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that new clinical data highlighting the companys second clinical product a fully informative genomic profile for hematologic malignancies being developed in collaboration with memorial sloankettering cancer center  read more foundation medicine partners with broadbased coalition to advance revolutionary new clinical trial design in lung cancer november      pdf  kb foundation medicine selected to provide comprehensive genomic testing platform for patients enrolled in master protocol trial cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that it has partnered with friends of cancer research as well as federal h read more foundation medicine announces  third quarter results november      pdf  kb clinical test volume increased to more than  in the period total revenues increased to  million cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that  foundationone™ tests were reported to ordering oncologists in t read more foundation medicine announces timing for third quarter  financial results and conference call october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that financial results for the companys third quarter ended september   will be released on wednesday november   the management team will host a conference call discussing the companys financial r read more foundation medicine identifies novel clinically actionable gene fusion ntrk in lung cancer data published in nature medicine october      pdf  kb cambridge massbusiness wire foundation medicine inc nasdaqfmi today announced that the discovery of a novel and potentially clinically actionable oncogenic gene fusion in lung cancer ntrk using foundationone™ was published in the current online edition of nature medicine  read more foundation medicine announces publication of analytic validation study of foundationone™ in nature biotechnology october      pdf  kb publication establishes standard of analytic performance for clinical application of nextgeneration sequencing in cancer cambridge massbusiness wire foundation medicine inc nasdaq fmi today announced that results from a month multiinstitution collaboration demonst read more foundation medicine announces closing of initial public offering and exercise of overallotment option september      pdf  kb cambridge massbusiness wire foundation medicine inc today announced the closing of its initial public offering of  shares of common stock at a public offering price of  per share before underwriting discounts which includes the exercise in full by the underwriters of their option to pur read more foundation medicine prices initial public offering of common stock september      pdf  kb cambridge massbusiness wire foundation medicine inc today announced the pricing of its initial public offering of  shares of common stock at a price of  per share before underwriting discounts all of the common stock is being offered by foundation medicine in addition the underwriters read more foundation medicine files registration statement for proposed initial public offering of common stock july      pdf  kb cambridge ma july    foundation medicine inc today announced the filing of a registration statement on form s with the securities and exchange commission for a proposed initial public offering of shares of its common stock all of the shares to be sold in the proposed offering will be offered by foundation medicine  fo read more new clinical data identifies high frequency of her alterations across multiple solid tumor types using foundationone™ june      pdf  kb cambridge mass and chicago  june    foundation medicine inc a molecular information company that brings comprehensive cancer genomic testing and analysis to routine clinical care today announced data demonstrating that its comprehensive genomic profile for cancer  read more actionable genomic alterations identified in  of clinical cancer cases profiled with foundationone™ may      pdf  kb cambridge mass and chicago  may    foundation medicine inc a molecular information company that brings comprehensive cancer genomic testing and analysis to routine clinical care today announced new data demonstrating that its comprehensive genomic profile  read more the us oncology network selects med fusion and foundation medicine to optimize molecular diagnostic testing and enhance the delivery of highquality precision medicine may      pdf  kb the woodlands texasbusiness wirephysicians in the read more foundation medicine to present clinical data on its foundationone™ cancer genomic profile at the  asco annual meeting may      pdf  kb cambridge mass may    foundation medicine inc a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care today announced that  abstracts highlighting the companys progress in clinical cancer genome sequ read more foundation medicine and memorial sloankettering cancer center announce partnership to advance patient care in hematologic cancers may      pdf  kb cambridge mass and new york  may    foundation medicine and memorial sloankettering cancer center today announced a partnership that brings together clinical genomic and computational expertise to advance patient care in hematologic cancers this  read more study published in journal of clinical oncology finds high concordance of genomic alterations in nsclc primary and matched metastatic tumor pairs april      pdf  kb cambridge mass and paris france  april    foundation medicine inc and the institut gustave roussy today announced the results of a nextgeneration sequencing study of primary and matched metastatic tumor pairs from  patients with nonsmall cell read more foundation medicine and agios announce diagnostic discovery collaboration for idh and idh cancer metabolism programs april      pdf  kb cambridge mass  april    foundation medicine inc and agios pharmaceuticals inc today announced a multiyear diagnostic partnership for agios lead programs in cancer metabolism these programs focus on developing new cancer metabolism inhibitors targeting tumors carrying mutations in either the idh or idh metabolic enzym read more foundation medicine to present cancer genomic research and clinical findings at the aacr annual meeting  march      pdf  kb cambridge mass march    foundation medicine inc a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care today announced the companys participation in multiple sessions and presentations at the american read more foundation medicine receives accreditation from the college of american pathologists march      pdf  kb cambridge mass march    foundation medicine inc today announced that it has received accreditation from the commission on laboratory accreditation of the college of american pathologists cap based on the results of a recent onsite laboratory inspection the us federal gover read more foundation medicine to present new data on foundationone™ a comprehensive cancer genomic assay at the th annual agbt meeting february      pdf  kb cambridge mass february    foundation medicine inc a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care today announced that new data on the clinical validation and application of  read more foundation medicine to present at upcoming investor conferences february      pdf  kb cambridge mass february    foundation medicine inc a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care today announced that members of the companys management team will present at the following upcoming investor conferenc read more foundation medicine appoints steven j kafka phd as chief business officer january      pdf  kb cambridge mass january    foundation medicine inc a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care today announced the appointment of steven j kafka phd to the newly created position of chief business officer in t read more foundation medicine expands series b financing to  million january      pdf  kb cambridge mass january    foundation medicine inc today announced an expansion of its series b financing raising an additional  million and bringing the total raised in the round to  million the new investors include bill gates evan jones and yuri milner adva read more foundation medicine to present at the st annual jp morgan healthcare conference january      pdf  kb cambridge mass january    foundation medicine inc a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care today announced that michael j pellini md president and chief executive officer will present an overview of the co read more new clinical data highlighting foundation medicines nextgeneration sequencing analysis in breast cancer to be presented at sabcs december      pdf  kb read more foundation medicine and ariad announce collaboration for genomic chracterization of patients in ap oncology program november      pdf  kb read more foundation medicine and astrazeneca announce genomic profiling collaboration november      pdf  kb read more foundation medicine to collaborate with eisai on international oncology trial october      pdf  kb read more foundation medicine announces  million series b financing september      pdf  kb read more foundation medicine and clovis oncology announce diagnostic collaboration august      pdf  kb read more win consortium to conduct a clinical trial using foundationonetm foundation medicines comprehensive genomic profile for cancer june      pdf  kb read more foundation medicine enters extensive collaboration to provide genomic information for clinical oncology programs june      pdf  kb read more foundation medicine announces new data using nextgeneration sequencing to detect cancerrelated mutations not identified by conventional methods june      pdf  kb read more foundation medicine to present at goldman sachs rd annual global healthcare conference may      pdf  kb read more foundation medicine launches foundationonetm may      pdf  kb read more new clinical data highlighting foundation medicines comprehensive cancer genomic profile to be presented at  asco annual meeting may      pdf  kb read more new data highlighting foundation medicines nextgeneration sequencing approach in clinical oncology to be presented at rd aacr annual meeting  march      pdf  kb read more foundation medicine announces collaboration with array biopharma march      pdf  kb read more foundation medicine and dana farbercancer institute identify novel genomic alterations in lung and colorectal cancer february      pdf  kb read more foundation medicine recieves clia certification for its genomic sequencing laboratory february      pdf  kb read more foundation medicine announces collaboration with sanofi january      pdf  kb read more foundation medicine appoints medical oncologist vincent a miller md as senior vice president of clinical development november      pdf  kb read more foundation medicine announces fourth major pharmaceutical company alliance october      pdf  kb read more foundation medicine closes expanded series a financing totaling  million october      pdf  kb read more data on foundation medicine’s comprehensive cancer diagnostic test presented at  european multidisciplinary cancer congress september      pdf  kb read more foundation medicine to present data on nextgeneration sequencing approach to cancer genome analysis at several upcoming industry conferences june      pdf  kb read more foundation medicine appoints kevin krenitsky md as chief operating officer june      pdf  kb read more foundation medicine announces results using nextgeneration sequencing to detect cancerassociated mutations in routine cancer tissue samples data presented at asco june      pdf  kb read more foundation medicine to present new data on its comprehensive cancer genomic test at asco  annual meeting may      pdf  kb read more foundation medicine announces clinical cancer genomics collaboration with celgene may      pdf  kb read more foundation medicine board of directors appoints michael j pellini md president and chief executive officer may      pdf  kb read more foundation medicine to present data on proprietary approach to optimizing nextgeneration cancer genome sequencing platform to enable clinical application at recomb  march      pdf  kb read more foundation medicine appoints gary palmer md as senior vice president of medical affairs and commercial development january      pdf  kb read more foundation medicine announces first large pharmaceutical company collaboration january      pdf  kb read more foundation medicine appoints molecular diagnostics industry leader maureen t cronin phd as senior vice president of research and product development november      pdf  kb read more foundation medicine created by cancer genomics pioneers to help bring personalized cancer medicine to routine clinical practice april      pdf  kb read more page     next last   view all items shareholder tools email alerts snapshot rss print email share facebook google linkedin twitter email rss close dialogwelcome backsign into your accountemail addresspasswordforgot passwordlog indonâ€™t have an accountyou can sign up onlinesign up